The below learning objectives are for the overall 2023 Annual Antimicrobial Stewardship Meeting. Session-specific learning objectives can be found on the agenda. Upon completion of the program learners will be able to:
- Develop a strategy to evaluate and reduce health disparities in antimicrobial use in individual practice settings
- Identify patients who may benefit from Beta-lactam TDM,
- Discuss approaches to launch or expand an antibiotic stewardship program in a community hospital
- Discuss evidence-based educational techniques and their application to infectious diseases education
- Design a plan for improving antimicrobial stewardship in an intensive care setting
- Explain factors contributing to inappropriate antibiotic use in outpatient settings
- List potential barriers to implementing Gram-negative treatment guidance
- Outline strategies for antibiotic stewardship programs to collaborate with clinical laboratories on diagnostic stewardship efforts
- Discuss clinical, social, and regulatory factors impacting future antibiotic use and resistance trends
- Describe a framework for combatting emerging antimicrobial resistance threats in the future
- Define de-escalation in terms of spectrum, route, and duration of therapy
- Describe the gaps in antibiotic and immunomodulatory therapy development
- Describe the latest recommendations for the treatment of Gram-negative non-fermenters
- Identify the therapeutic gaps in guidelines associated with treatment of Staphylococcus aureus infections
- Discuss the history, development, and utility of Antimicrobial Susceptibility Testing methodologies
- Describe the approaches used to develop susceptibility interpretive criteria in different agencies (e.g. CLSI, FDA, USCAST, EUCAST)
- Identify emerging technologies for rapid microbial identification and susceptibility testing in inpatient and outpatient settings
- Describe the importance of collaboration between antibiotic stewardship programs and internal medicine and other clinicians
- Outline recent updates to CDC ACIP vaccine recommendations and their supporting clinical evidence
- Discuss the importance of the microbiome and fecal microbiota transplantation in prevention of C. difficile infection and recent updates on evaluation and management of C. difficile infection
- Identify major developments published in the ID literature from May 2022 thru April 2023